Pharmabiz5h
CAGE Bio begins phase 2b clinical trial for CGB-500, a breakthrough topical JAK inhibitor for moderate to severe atopic dermatitis
CAGE Bio begins phase 2b clinical trial for CGB-500, a breakthrough topical JAK inhibitor for moderate to severe atopic dermatitis: San Carlos, California Saturday, January 11, 20 ...
Pharmabiz7h
Newron Pharma, Myung In Pharm ink license agreement to develop, manufacture & commercialize Newron’s evenamide in South Korea
Newron Pharma, Myung In Pharm ink license agreement to develop, manufacture & commercialize Newron’s evenamide in South Korea: Milan Saturday, January 11, 2025, 16:00 Hrs [IST] ...
Pharmabiz4d
Indian healthcare sees medical networking as catalyst for quality services in remote regions
The Indian healthcare sector sees emergence of medical networking to revolutionise quality services in remote regions. This is despite the resource and infrastructural constraints leading to the ...
Pharmabiz4d
Santhera enters supply and distribution agreement with Clinigen Group for Agamree to treat patients with Duchenne muscular dystrophy
Santhera Pharmaceuticals announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of Agamree (vamorolone) in countries where the product is not ...
Pharmabiz7d
Capricor Therapeutics seeks US FDA approval for deramiocel for the treatment of Duchenne muscular dystrophy
Capricor Therapeutics, a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced the completion of the submission of its ...
Pharmabiz5d
Eton Pharma acquires Galzin, an US FDA approved treatment of ultra-rare metabolic condition of Wilson disease
Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced that it has acquired Galzin (zinc acetate). “This ...
Pharmabiz5d
Parliamentary panel asks DoE to furnish justification on denying proposal for setting up of NIMERs
Expressing its concern over the Department of Expenditure's (DoE) decision to turn down the Department of Pharmaceuticals (DoP)’s proposal for setting up separate National Institutes for Medical ...
Pharmabiz7d
GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps
GSK plc announced that the China National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy with ...
Pharmabiz5d
Bayer announces Federal Court of Australia brings an end to Roundup litigation
The Federal Court of Australia brought an end to the last Roundup case in Australia, closing all pending injury litigation there. The Court granted the plaintiffs’ request to discontinue the Fenton ...
Pharmabiz4d
Oculis Holding’s OCS-05 phase 2 ACUITY trial in acute optic neuritis meets primary safety endpoint and key secondary efficacy endpoints
Oculis Holding AG, a global biopharmaceutical company purposefully driven to save sight and improve eye care, announced positive topline results with OCS-05 in the phase 2 ACUITY trial, which met the ...
Pharmabiz4d
eMBR Genomics partners with Axio BioPharma to make MKLP1 Pro antibodies commercially available
In a milestone for cellular research, eMBR Genomics and Axio BioPharma announce the first commercial availability of MKLP1 Pro antibodies, KIF23 gene – the same tools used by the world’s leading ...
Pharmabiz8d
Hutchmed to divest its 45% equity interest in SHPL to GP Health Service Capital & Shanghai Pharma for approx. US$ 608 million
Hutchmed (China) Limited, an innovative, commercial-stage, biopharmaceutical company, announces that it has entered into two agreements to divest its 45% equity interest in Shanghai Hutchison ...